Trevi Therapeutics (TRVI) Tops Q4 EPS by 4c
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Join SI Premium – FREE
Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.06), $0.04 better than the analyst estimate of ($0.10).
For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- CRH agrees to buy Arcosa in $8.5B all-cash deal
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
